Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230954 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
A Phase 2 study, sponsored by University of South Alabama.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04230954: Clinical Trial Phase 2 study, sponsored by University of South Alabama.
NCT04230954 is a Phase 2 study that was terminated before completion, run by University of South Alabama. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230954, a Phase 2 study, was terminated before completion, sponsored by University of South Alabama.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Drug: Cabozantinib Drug: Pembrolizumab
Primary Outcome
Six months progression free survival as defined by RECIST v1.1 measured from signed written consent to the date of first documented tumor progression using RECIST v1.1, or death due to any cause or 24 months after the end of study treatment.
Interventions
- DRUG Cabozantinib 40 MG oral once a day
- DRUG Pembrolizumab 200 mg IV every 3 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
Why NCT04230954 stopped before completion
NCT04230954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib 40 MG oral once a day is the first listed.
NCT04230954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04230954 about?
NCT04230954 is a clinical study titled "Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer". Drug: Cabozantinib Drug: Pembrolizumab
What is the current status of trial NCT04230954?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-04-16. Estimated completion is 2022-02-16.
What interventions are being tested in trial NCT04230954?
The interventions under investigation include: Cabozantinib 40 MG oral once a day (DRUG), Pembrolizumab 200 mg IV every 3 weeks (DRUG).
Who is sponsoring clinical trial NCT04230954?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04230954's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI